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ABSTRACT
Objectives: To describe smoking trajectories from early
adolescence into mid-life and to examine the effects of
these trajectories on health and all-cause mortality.
Methods: A nationally representative birth cohort study
including 3387 men and women followed up since their
birth in 1946 in England, Scotland and Wales. The main
outcome measure is all-cause mortality by age 60 years
and rate of decline in forced expiratory volume in
1 second (FEV1).
Results: Eighteen per cent of the sample were
categorised as lifelong smokers (smokers at all six waves
at ages 20, 25, 31, 36, 43, 53 years), of whom 90% had
begun smoking by age 18 years. By age 60 years, 10% of
all lifelong smokers had died. They had a threefold
increase in mortality rate compared with never smokers
(hazard ratio (HR) 3.2, 95% confidence interval (CI) 2.1 to
4.8). For predominantly smokers (smokers for at least four
of the six data collections), mortality rate remained higher
than never smokers (HR 1.6, 95% CI 1.0 to 2.5).
Predominantly non-smokers did not differ from those who
never smoked (HR 1.3, 95% CI 0.9 to 2.0). Using the most
recent smoking status available, current smokers had
more than double the risk of mortality compared with
never smokers (HR 2.4, 95% CI 1.6 to 3.5). Lifelong
smokers and predominantly smokers had a greater rate of
decline in lung function than never smokers (regression
coefficients 218 ml/year, 95% CI 222 to 213; 26, 95%
CI 210.3 to 21.7 respectively). For current smokers, the
decline was 8.4 ml/year (95% CI 212.0 to 25.0) faster
than never smokers.
Conclusions: The strength and differentiation of adverse
effects identified by using simplified smoking behaviours
has highlighted the advantages of obtaining further
information on lifelong smoking behaviour from former
smokers, rather than just current smoking status.
Smoking is a major cause of global mortality and the
single most important risk factor in developed
countries. Total tobacco-attributable deaths are
projected to rise from 5.4 million in 2005 to 6.4
million in 2013 and 8.3 million by 2030 under the
baselinescenarioofMathersandLoncor.
1IntheUK,it
isestimatedthateachyear114 000diefromsmoking-
attributable causes, or about a fifth of all UK deaths.
2
In tackling this issue, it is important to consider the
relative performance of different measures for smok-
ing behaviour over the lifespan in terms of their
assessment of the strength of such adverse effects.
As the evidence for harmful effects of tobacco
use has mounted, epidemiological research has
progressed from simply identifying health risks
associated with smoking to more detailed studies
of the long-term effects of different smoking
behaviours on mortality and morbidity. Previous
studies that used a single baseline assessment of
smoking history found risks from smoking that
include: lung cancer risk,
3 excess mortality,
4 cardi-
ovascular disease risk,
56and poor lung function.
378
Several well-known longitudinal studies have also
identified the role of smoking in the development
of chronic disease, in the risk of premature
mortality
3 9–12 and in the health benefits associated
with smoking cessation.
13 Data from the American
Cancer Society’s Cancer Prevention Study II (ACS
CPS-II) revealed that those who quit smoking
before age 50 years halved the risk of dying in the
following 15 years compared with continuing
smokers.
13 Doll and colleagues reported that,
among male doctors, prolonged cigarette smoking
from early adult life tripled age-specific mortality
rates, but cessation at age 50 years halved the
hazard, and cessation at age 30 years avoided
almost all of it.
10
Accurate and detailed classification of smoking
status is essential to determine the differential
effects of cessation and to assist with the
comparison of results across studies. There is,
however, substantial variation in the assessment of
smoking status and the way data are analysed. In
some longitudinal studies, smoking behaviour is
measured as current, or most recently available,
smoking status.
14 15 This may be quantified further
via retrospective data on the number of cigarettes
smoked per day (intensity)
16 and duration of
smoking,
17 with smoking behaviour calculated as
their product and reported in terms of pack–
years.
18–21
There have also been several attempts to
categorise adolescent smoking behaviour.
22–24 In
2004, Audrain-McGovern and colleagues identified
four adolescent smoking trajectories (never smo-
kers, experimenters, earlier/faster adopters and
later/slower smoking adopters).
25 These smoking
trajectories had significantly different rates and
intensity of smoking progression,
25 but few studies
have prospective longitudinal data to follow such
trajectories into adult life.
The Medical Research Council National Survey
of Health and Development (NSHD) is a popula-
tion-based birth cohort study that provides an
opportunity to study lifelong smoking behaviour
and its influence on mid-life health outcomes.
26
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trajectories in this cohort from early adolescence into mid-life;
(2) to examine the relationships between these smoking
trajectories and adult all-cause mortality to age 60 years and
rate of change in lung function from age 43 to 53 years; and (3)
to compare the strength of these relationships with those found
using the most recent smoking status available and with those
from smoking status assessed at 25 years of age.
METHODS
The NSHD is a social class stratified birth cohort of 5362 births
(2815 men and 2547 women) in the first week of March 1946 in
England, Scotland and Wales. There have been 21 follow-ups of
the main cohort since their birth up to the most recent contact
in 1999 at age 53 years. A total of 3035 cohort members (1472
men, 1563 women) provided information at age 53 years. This
corresponds to a participation rate of 70.5% among those still
alive and resident in England, Wales or Scotland, and 89.6% for
whom contact was attempted. Contact was not attempted for
individuals who had previously refused to take part (n=648),
were untraced since last contact at 43 years (n=266), were
living abroad (n=583) or had already died (n=476). Those
who responded at age 53 years were in most respects
representative of the national population of a similar age.
27
Ethics approval for this study was given by the North Thames
Multicentre Research Committee.
Current cigarette smoking status (‘‘yes’’, ‘‘no’’) and the
number of cigarettes smoked per day were obtained in six waves
(at ages 20, 25, 31, 36, 43, 53 years). Cohort members who
provided an affirmative response to being current cigarette
smokers, regardless of the quantity of cigarettes smoked per
day, were classified as ‘‘smokers’’, while those who provided a
negative response were classified as ‘‘non-smoker’’. From age 36
onwards, research nurses obtained information on smoking
during a home interview, while data from earlier years were
collected by postal questionnaire. A total of 1845 (34%)
participants provided information on smoking at all six waves,
2635 (49%) had missing information for at least one wave, and
882 (17%) failed to provide any smoking data (fig 1).
The sample for this analysis comprised those who provided
data for at least three waves (n=3387) and for whom missing
data are not sequential (fig 1). Cohort members were classified
into one of four smoking trajectories:
1. ‘‘Never smoker’’: a non-smoker at all available data
collections
2. ‘‘Predominantly non-smoker’’: a non-smoker for at least
three data collections
3. ‘‘Predominantly smoker’’: a smoker at four or more of the
data collections
4. ‘‘Lifelong smoker’’: a smoker at all available data collec-
tions.
In cases where data were missing from one or more waves,
classification was based on the smoking status at the majority
of data collections. Thus, if at three out of four data collections
the cohort member reported being a smoker, then they were
classified as ‘‘predominantly smoker’’. To permit a comparison
with results from the smoking trajectories, two single time
point measures were also used: the most recent smoking status
available from cohort members (including from those who had
died) and smoking status at age 25 years.
Smoking dosage to age 53 years was measured by the average
number of cigarettes smoked per day: determined from the
pack–years of smoking calculated at each data collection. Age at
which the cohort member began smoking was recorded retro-
spectively at age 20 years.
In order to evaluate the performance of the various measures
of smoking behaviour, smoking-related health outcomes,
namely all-cause mortality,
3 9–12 and changes in lung func-
tion,
28 29 were chosen. Since age 26 years, cohort members have
been flagged for death notification on the National Health
Service Central Register. In order to ensure that cohort members
who died had provided sufficient information on smoking
behaviour, time to all-cause mortality was taken from age
36 years onwards. Between 36 and 60 years, there were 211
deaths. Lung function was available to all cohort members and
was denoted by forced expiratory volume in 1 second (FEV1)
measured at ages 43 and 53 years using the Micromedical
turbine electronic spirometer, administered by a trained nurse.
The rate of lung function change per year over the two time
Figure 1 Smoking data follow-up in the Medical Research Council National Survey of Health and Development.
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43 years/10), with a decline recorded as a negative value.
Statistical analyses
Cox proportional hazard models were used to investigate the
relations between each measure of smoking behaviour and all-
cause mortality.
30 In order to obtain the hazard ratios (HRs) for
all-cause mortality, follow-up time (in months) was from the
cohort’s 36th birthday until the first of death, emigration or the
end of March 2006, the cohort’s 60th birthday. If death had not
occurred, follow-up was treated as censored. The assumption of
proportional hazards (PH) was evaluated both by the inspection
of the Kaplan–Meier survival curves and by testing the null
hypothesis that the PH assumption holds for each measure of
smoking behaviour. These were obtained from the statistical
package STATA 8.2, commands stphplot and stphtest respectively.
Linear regression was used to examine the relation between
rate of FEV1 change from age 43 to 53 years and each measure of
smoking behaviour. The regression coefficients and the 95%
confidence intervals (CIs) were adjusted for FEV1 at baseline
(43 years) and height at age 53 years.
18 As the main aim of this
paper was to compare the results obtained from the various
measures of smoking behaviour, rather than to examine the
predictors of all-cause mortality or lung function, only results
from univariable analyses were presented. All analyses were
carried out on data from at least three waves (n=3387). A
sensitivity analysis was carried out by repeating all analyses on
those with complete smoking status data (n=1845). As the
findings from these analyses were broadly similar, results from
the larger sample size are presented here.
RESULTS
Based on the 1845 cohort members, who completed all six
waves of questionnaires, the prevalence of smoking more than
halved for men from 55% at age 20 years to 21% by age 53 years
(fig 2). The reduction was less for women, declining from 49%
at age 20 years to 24% at age 53 years. In this cohort, a higher
proportion of smokers at age 25 years (p,0.001) provided
incomplete data (48%), compared with the never-smoking
group (31%). Those with incomplete smoking data were more
likely to be male (54% incomplete vs 47% complete), have
primary or lower education level (72% vs 61%) and come from a
manual social class background (37% incomplete vs 29%
complete). Of the 3387 cohort members who provided
information for smoking trajectories, there was only one for
whom mortality status was not available.
More than one in four of the cohort members (28%) were
lifelong non-smokers (table 1), with almost a third (32%) of all
women belonging to this group. Nearly a fifth (18%) of the
sample were categorised as lifelong smokers, of whom 30%
started smoking before age 16 years and 90% had begun by age
18 years. Of lifelong smokers, men were more likely to start
smoking by age 16 years than women (56% vs 39%). In the
predominantly non-smoking group, more than two out of three
(67%) had already stopped at least once by 25 years, and only
3% were smokers at their most recent report. In addition, only
one individual had smoked more than 15 cigarettes per day. In
contrast, around one out of five predominantly smokers (17%)
Table 1 Percentage of National Survey of Health and Development cohort members in each smoking
trajectory category by smoking characteristics
Smoking characteristics
Smoking trajectories n (%)
Never smoker
(n=950)
Predominantly non-
smoker (n=1101)
Predominantly
smoker (n=715)
Lifelong smoker
(n=621)
Age at initiation (n)
,16 years (489) N/A 164 (22.8) 140 (21.3) 185 (32.2)
>16 years (1459) N/A 554 (77.2) 516 (78.7) 389 (67.8)
Total (1948) N/A 718 (100) 656 (100) 574 (100)
Smoking status at 25 years (n)
Never (920) 813 (100) 91 (9.8) 16 (2.7) N/A
Former (742) N/A 624 (67.2) 118 (19.6) N/A
Current (1163) N/A 213 (23.0) 469 (77.8) 481 (100)
Total (2825) 813 (100) 928 (100) 603 (100) 481 (100)
Most recent smoking status (n)
Never (950) 950 (100) N/A N/A N/A
Former (1531) N/A 1065 (96.7) 466 (65.2) N/A
Current (906) N/A 36 (3.3) 249 (34.8) 621 (100)
Total (3387) 950 (100) 1101 (100) 715 (100) 621 (100)
Smoking dosage: average number of
cigarettes per day (n)
1–14 (1305) N/A 557 (99.8) 587 (82.7) 161 (25.9)
15+ (584) N/A 1 (0.2) 123 (17.3) 460 (74.1)
Total (2839) N/A 558 (100) 710 (100) 621 (100)
N/A, not applicable.
Figure 2 The percentage* of current smokers from age 20 years in
1966 to age 53 years in the NSHD cohort (n=1845).
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cigarettes per day. Of those in the cohort that were recorded as
being former smokers for their most recent status, 30% were
predominantly smokers over their lifetime.
All-cause mortality
For those with smoking trajectory data, 211 study members had
died between the age of 36 and 60 years: 120 men and 91
women. Of lifelong smokers, the probability of surviving past
the age of 60 years was 0.88 compared with 0.96 for never
smokers (fig 3). From table 2, this corresponds to a threefold
increase in the hazard ratio for lifelong smokers (HR=3.2, 95%
CI 2.1 to 4.8). Predominantly non-smokers did not differ
significantly from those who never smoked. For predominantly
smokers, the mortality rate was almost halved compared with
lifelong smokers, but remained 60% higher than never smokers.
Using the most recent smoking status available, current
smokers had more than double the risk of mortality by age
60 years compared with those who had never smoked, but less
than the hazard ratio indicated by lifelong smoking status from
trajectories. Former smoking status suggested a higher risk of
all-cause mortality, if not statistically significant, than never
smokers (HR=1.3, 95% CI 0.8 to 1.9), which was similar to the
hazard ratio indicated from trajectories by the predominantly
non-smoking category. Similar hazard ratios were obtained
using smoking status at age 25 years. However, male former
smokers at this age had about twice the risk of dying by
60 years compared with those who had never smoked.
Rate of change in lung function from age 43 to 53 years
Lifelong smokers had a marked decline in lung function between
43 and 53 years (218.0 ml/per year, 95% CI 222.3 to 212.8)
compared with never smokers, and three times that estimated
between predominantly smokers and never smokers (table 3).
No evidence for a difference in the rate of decline was found
between predominantly non-smokers and never smokers. From
the most recent smoking status available, the lung function of
current smokers was found to have declined at a rate of 8.4 ml/
year (95% CI 212.0 to 25.0) faster than never smokers. Former
smokers recorded no significant difference in rate of decline in
lung function relative to those who had never smoked. Similar
results were obtained for rates of change in lung function using
smoking status at age 25 years.
DISCUSSION
Prospective data from the NSHD, spanning more than 30 years,
has produced stark evidence for the differential impact of
cigarette smoking behaviours on mortality rate and lung
function decline. Moreover, the strength of this evidence differs
according to the way smoking behaviour is characterised.
Lifelong smokers, as classified by their smoking trajectory,
were at the greatest risk of all-cause mortality and, by age
60 years, more than 10% had died. Lifelong smokers also had the
greatest rate of lung function decline between ages 43 and
53 years compared with those who had never smoked. Weaker
effects were identified by using the single time point measures
of either current (most recent) smoking status or smoking
status at age 25 years. Smoking trajectories also quantified the
impact of cessation by distinguishing the risk of mortality and
decline in lung function between those who had been
predominantly smokers throughout their life from predomi-
nantly non-smokers.
These results are broadly consistent with other studies. Doll
et al
10 found that smoking from early adult life among British
doctors tripled age-specific mortality rates compared with
lifelong non-smokers. The ACS CPS-II cohort study found that
continuing smokers had around twice the overall mortality rates
of those who had never smoked.
13 There is also general
Table 2 Hazard ratio and 95% confidence intervals for all-cause mortality between ages 36 and 60 years by
smoking trajectories, most recent smoking status and smoking status at 25 years
All-cause mortality HR (95% CI)
Men (n=1647) Women (n=1639) All (n=3286)
Smoking trajectories (n)
Never smoker (921) 1 1 1
Predominantly non-smoker (1086) 1.46 (0.83 to 2.56) 0.99 (0.51 to 1.92) 1.30 (0.86 to 1.99)
Predominantly smoker (692) 1.82 (1.02 to 3.25) 1.13 (0.55 to 2.35) 1.61 (1.03 to 2.50)
Lifelong smoker (587) 2.34 (1.30 to 4.19) 4.21 (2.41 to 7.33) 3.21 (2.14 to 4.79)
Most recent smoking status (n)
Never smoker (921) 1 1 1
Former smoker (1114) 1.30 (0.74 to 2.27) 1.09 (0.56 to 2.11) 1.28 (0.84 to 1.95)
Current smoker (1251) 2.32 (1.37 to 3.92) 2.42 (1.42 to 4.13) 2.39 (1.64 to 3.48)
Smoking status at 25 years (n)
Never smoker (917) 1 1 1
Former smoker (738) 2.35 (1.32 to 4.18) 0.56 (0.25 to 1.27) 1.50 (0.97 to 2.32)
Current smoker (1152) 1.59 (0.90 to 2.79) 2.24 (1.32 to 3.79) 1.90 (1.29 to 2.79)
Missing (479) 1.71 (0.90 to 3.25) 2.21 (1.14 to 4.26) 1.95 (1.24 to 3.07)
Figure 3 Kaplan–Meier estimates of the proportion of cohort members
who are still alive by the smoking trajectories (n=3286).
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smoking. In the study of British doctors, it was determined
that cessation by age 50 years halved the increased risk, and
cessation by 30 years avoided almost all of it.
10 Data from the
ACS CPS-II also revealed that those who quit smoking before
age 50 years halved the risk of dying in the following 15 years
compared with continuing smokers.
13 In the NSHD study, a
gradient was found for mortality rates according to smoking
duration. Predominantly non-smokers, that is those who
reported being non-smokers for the majority of—rather than
all—data collections, had similar all-cause mortality risk by age
60 years to lifelong non-smokers.
The marked acceleration in the rate of decline in lung
function between age 43 and 53 years for lifelong smokers and
predominant smokers when compared with lifelong non-
smokers is consistent with other cohort studies.
28 29 However,
most of these other studies have not compared the relative
impact of smoking behaviour beyond that of current or former
smokers.
The main limitation of this study lies in the generalisability of
results due to cohort effects, as most smoking exposure had
already occurred prior to the 1980s and before widespread anti-
smoking programmes. Furthermore, the cohort carries risks
associated with growing up at a time of heavy smoking patterns
among parents.
31 The prevalence of smoking by men and
women in their thirties was slightly higher than that in the 1958
birth cohort.
32 However, the age-related decline in smoking
observed here is in broad agreement with the secular trend in
the population over the last four decades.
33–35 Another limitation
of the study is that self-reported data do not always give an
accurate assessment of smoking habits,
36 and this may lead to
misclassification and conservative estimates of the effect of
smoking.
37 Longitudinal prospective data provide the opportu-
nity to investigate the consistency of repeated smoking
behaviour reports.
38 The main strengths of the study are the
inclusion of women as well as men in a nationally representa-
tive sample, with prospective measures of smoking behaviour
spanning from early adulthood to middle age.
CONCLUSION
The methodological strategy chosen to measure smoking
behaviour has implications for the strength of findings available
from a study. From the NSHD, the use of smoking behaviour
trajectories has identified markedly stronger adverse effects for
all-cause mortality and decline in lung function for lifelong
smokers than the results obtained using current smoking status
Table 3 Regression coefficients and 95% confidence intervals for the rate of FEV1 (ml/year) change between age 43 and 53 years by smoking
trajectories, most recent smoking status and smoking status at 25 years*
Regression coefficient (95% CI){
Men (n=1234) Women (n=1306) All (n=2540){
Smoking trajectories (n)
Never smoker (737) 0 0 0
Predominantly non-smoker (896) 1.20 (24.80 to 7.19) 1.30 (23.26 to 5.76) 1.61 (22.13 to 5.34)
Predominantly smoker (532) 28.04 (214.76 to 21.31) 26.37 (211.58 to 21.16) 26.0 (210.26 to 21.74)
Lifelong smoker (375) 224.8 (232.25 to 216.91) 215.44 (221.20 to 29.68) 217.61 (222.34 to 212.84)
Most recent smoking status (n)
Never smoker (737) 0 0 0
Former smoker (909) 21.56 (27.50 to 4.38) 22.51 (27.15 to 2.12) 0.82 (24.59 to 2.94)
Current smoker (894) 212.91 (219.16 to 26.66) 26.13 (210.53 to 1.73) 28.44 (212.21 to 24.68)
Smoking status at 25 years (n)
Never smoker (722) 0 0 0
Former smoker (588) 1.17 (25.61 to 7.96) 0.39 (24.57 to 5.35) 0.5 (23.65 to 4.71)
Current smoker (839) 214.32 (220.44 to 28.20) 210.1 (214.72 to 5.48) 211.0 (214.86 to 27.21)
Missing (391) 26.34 (213.69 to 1.02) 223.3 (28.20 to 3.54) 23.40 (28.13 to 1.33)
*Adjusted for FEV1 level at age 43 years (baseline) and height at age 53 years.
{Negative coefficient refers to a decline in lung function.
{n for sample with complete data.
What is already known on this subject
c The health risks as a consequence of smoking are well
documented.
c Few studies have nationally representative prospective data
for both men and women on smoking from early adolescence
to middle age and hence are unable to assess reliably the
differential effects of smoking behaviours.
What this study adds
c This study uses data from a nationally representative birth
cohort to compare the performance of three measures of
smoking status: simplified behaviours based on lifelong
histories of smoking, with current smoking status and smoking
status at age 25 years.
c For all-cause mortality and decline in lung function, the effects
identified for lifelong smokers were stronger than those
obtained for the other two smoking measures based on
smoking status at a single time point.
c The use of lifelong smoking behaviours also differentiated the
risks of mortality and decline in lung function between
predominantly smokers and predominantly non-smokers.
Policy implications
In considering methodological strategies to assess the effects of
smoking behaviours, this study illustrates the benefits of using
information from the participant’s lifelong history of smoking.
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also enabled the detection of differential risks for mortality and
decline in lung function between predominantly smokers and
predominantly non-smokers. This has highlighted the advan-
tages of forming simplified smoking behaviour classifications by
collecting detailed information from former and current
smokers about their lifelong history of smoking behaviour.
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